Ciclofilin Pharma forms liver disease SAB

Closely-held Ciclofilin Pharmaceuticals has assembled a world-class team of scientists and clinicians for its scientific advisory board (SAB) to guide the company through its drug development program for its lead drug candidate, CPI-431-32, for the treatment of HBV and liver disease.

The company’s SAB will be chaired by Dr. Philippe Gallay, Prof. of The Scripps Research Institute, with members that include Dr. Tarek Hassanein, Prof. of medicine, UCSD School of Medicine, Dr. Keith Anderson, SVP of technical operations with ProNAi, and Timothy Schroeder, CEO of CTI Clinical Trial & Consulting.

Ciclofilin’s CPI-431-32 is a cyclophilin inhibitor specifically designed to target the hepatitis B virus, and has demonstrated anti-fibrotic properties associated with the clinical sequelae of chronic HBV infection.

“Our SAB members have a deep understanding of how cyclophilin inhibition works, as well as the clinical consequences and challenges faced with treatments of HBV and liver disease, the design and implementation of clinical trial protocols, regulatory processes, the execution of non-clinical studies, and the management of drug manufacturing and supply chain issues,” Ciclofilin CEO, Dr. Robert Foster, said in a statement.

“Having access to these industry leaders and their collective networks is a tremendous advantage for our company,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.